Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …

Background Despite tremendous advances in cancer research, breast cancer (BC) remains
a major health concern and is the most common cancer affecting women worldwide. Breast …

Immune-mediated dormancy is when the immune system keeps proliferating tumor cells
unchanged, mostly via cytotoxic activity of immune cells. Cancer dormancy, especially …

Abstract Background Cancer-associated fibroblasts (CAFs) are molecularly heterogeneous
mesenchymal cells that interact with malignant cells and immune cells and confer anti-and …

Locally advanced nonsmall cell lung cancer, due to its varying prognosis, is grouped
according to TNM stage IIIA, IIIB and IIIC. Developments over the last 3 years have been …

Purpose: LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent
immunomodulatory properties in preclinical models. We conducted a phase I dose …

Immune checkpoint inhibitors (ICIs) are novel treatments that significantly improve the
survival time of MIBC patients, but immunotherapeutic responses are different among MIBC …

Background: Tumor microenvironment is essential for breast cancer progression and
metastasis. Our study sets out to examine the genes affecting stromal and immune infiltration …

Pancreatic adenosquamous carcinoma (PASC)—a rare pathological pancreatic cancer (PC)
type—has a poor prognosis due to high malignancy. To examine the heterogeneity of PASC …

Background Lung cancer is the leading cause of cancer-related mortality globally.
Discovering effective biomarkers for early diagnosis and prognosis is important to reduce …